Peculiarities of administration of medications to patients with circulatory system diseases within the framework of the federal program of preferential provision of medicines
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.065
Abstract
Objective: to analyse of medicines prescriptions for federal beneficiaries with circulatory system diseases and to identify the main trends in the implementation of the federal program for the provision of necessary medicines in the Samara Region in 2014–2017.
Material and methods. The authors reviewed the nomenclature of medicines used to treat circulatory system diseases (CSDs) and distributed to the population of the Samara Region as part of the federal program for the provision of necessary medicines for the period from 2014 to 2017. The methods of comparative, retrospective, logical, graphical and content analysis, the method of data grouping according to Anatomical Therapeutic Chemical classification and methods of descriptive statistics were used.
Results. In 2014–2017 the share of financial costs for the purchase of medicines in the total budget of the federal program for the provision of necessary medicines in the Samara Region did not exceed 6%. Still, in physical terms (in terms of the number of packages) the share of medicines of this pharmacotherapeutic group in the federal program for the provision of necessary medicines averaged about 25%. Nomenclature of medicines of the analyzed group prescribed to federal beneficiaries in 2014–2017 ranged from 90 to 107 nomenclature items. The number of international nonproprietary names (INN) decreased from 51 in 2014 to 36 in 2017. During the period under review, there was a decrease in the acquisition cost of medicines for the treatment of circulatory system diseases and the weighted average cost of one package (by 63% and 53%, respectively).
Conclusion. Perindopril-containing medicines occupied the maximum consumption volumes in monetary terms. There was a decrease in the average cost of one package in 2017, which may be associated with the replacement of original medicines with generics and a concomitant reduction in the number of INN within the subgroup.
About the Authors
I. K. PetrukhinaRussian Federation
Irina K. Petrukhina – Dr. Pharm. Sc., Associate Professor, Chief of Chair of Pharmacy Management and Economics, Dean of the Faculty of Pharmacy
WoS ResearcherID: S-6142-2016; RSCI SPIN-code: 3642-4547
89 Chapayevskaya Str., Samara 443099, Russia
R. I. Yagudina
Russian Federation
Roza I. Yagudina – Dr. Pharm. Sc., Professor, Chief of Chair of Drug Supply and Pharmacoeconomics
8 bld. 2 Trubetskaya Str., Moscow 119991, Russia
N. V. Veyner
Russian Federation
Nadezhda V. Veyner – MD, PhD, Head of Department of Pharmacy and Drug Supply
73 Leninskaya Str., Samara 443020, Russia
T. K. Ryazanova
Russian Federation
Tatyana K. Ryazanova – PhD (Pharm.), Associate Professor, Chair of Pharmacy Management and Economics
Scopus Author ID: 55810046000; WoS ResearcherID: H-3398-2015; RSCI SPIN-code: 1489-9183
89 Chapayevskaya Str., Samara 443099, Russia
E. P. Gladunova
Russian Federation
Elena P. Gladunova – Dr. Pharm. Sc., Professor, Chair of Pharmacy Management and Economics
RSCI SPIN-code: 3713-5310
89 Chapayevskaya Str., Samara 443099, Russia
V. A. Kurkin
Russian Federation
Vladimir A. Kurkin – Dr. Pharm. Sc., Professor, Chief of Chair of Pharmacognosy with Botany and Herbal Medicine Basics
Scopus Author ID: 25023727600; WoS ResearcherID: L-7663-2015; RSCI SPIN-code: 1974-5537
89 Chapayevskaya Str., Samara 443099, Russia
P. R. Blinkova
Russian Federation
Polina R. Blinkova – Postgraduate, Chair of Pharmacy Management and Economics
89 Chapayevskaya Str., Samara 443099, Russia
E. N. Zaitseva
Russian Federation
Elena N. Zaitseva – Dr. Med. Sc., Associate Professor, Chief of Lebedev Chair of Pharmacology
Scopus Author ID: 56735950700; WoS ResearcherID: P-6647-2015; RSCI SPIN-code: 8679-2730
89 Chapayevskaya Str., Samara 443099, Russia
References
1. Chazova I.E., Oschepkova E.V. The fight against cardiovascular diseases: problems and solutions at the present stage. Vestnik Roszdravnadzora. 2015; 5: 7–10 (in Russ.).
2. World Health Organization. Cardiovascular diseases. Available at: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (accessed 10.03.2021).
3. Shalnova S.A., Konradi A.O., Karpov Yu.A., et al. Cardiovascular mortality in 12 Russian Federation regions – participants of the “Cardiovascular Disease Epidemiology In Russian Regions” study. Russian Journal of Cardiology. 2012; 17 (5): 6–11 (in Russ.).
4. Vishnevsky A., Andreev E., Timonin S. Mortality from cardiovascular diseases and life expectancy in Russia. Demographic Review. 2016; 3 (1): 6–34 (in Russ.).
5. Shikhova Yu.A., Berezhnova Т.А., Klepikov О.V. Assessment of the level of blood circulation system diseases based on population appealability of medical care. Journal of New Medical Technologies, eEdition. 2017; 1: 86–94 (in Russ.).
6. Federal State Statistics Service. Russian statistical yearbook 2019. Available at: https://gks.ru/bgd/regl/b19_13/Main.htm (accessed 10.03.2021) (in Russ.).
7. Fatenkov O.V., Panisheva Ya.A., Galkina M.A., Sytdykov I.Kh. Pharmacoeconomics of treatment patients with high level hypercholesterolemia. Science and Innovations in Medicine. 2019; 4 (1): 26–31 (in Russ.).
8. Federal State Statistics Service. Regions of Russia. Social and Economic Indicators – 2019. Available at: https://gks.ru/bgd/regl/b19_14p/Main.htm (accessed 10.03.2021) (in Russ.).
9. Petrukhina I.K., Ryazanova T.K., Yagudina R.I., Gladunova E.P. Particularities of preferential provision of medicines of elderly patients in Privolzhsky Federal District. Advances in Gerontology. 2018; 31 (5): 789–97.
10. ConsultantPlus. Diseases of the circulatory system (I00–I99). Available at: http://www.consultant.ru/document/cons_doc_LAW_141711/5f190bf6abdd7221528e7d83aa951e00cd93c836/ (accessed 10.03.2021) (in Russ.).
11. Maksimova T.M., Lushkina N.P., Ogryzko Ye.V. The issues of assessment of medical support of patients with pathology of blood circulation system. Problems of Social Hygiene, Public Health and History of Medicine, Russian Journal. 2012; 6: 3–7 (in Russ.).
12. Abuov D.Zh., Grjibovski A.M., Kalmantaeva Zh.A., et al. Coverage of preferential population groups for antihypertensive medicines in Almaty, Kazakhstan. Human Ecology. 2014; 12: 21–5 (in Russ.).
13. Strekalova N.S., Kuznetsov D.A. The studying of medicinal maintenance of the citizens having the right to the state social help in territory of Tambov area. Journal of New Medical Technologies. 2012; 19 (4): 181–3 (in Russ.).
14. Kuznetsova A.M. Some aspects of providing medicines for the population entitled to benefits in the Republic of Tatarstan (the period from 2009 to 2012). The Bulletin of Contemporary Clinical Medicine. 2013; 6 (1): 97–100 (in Russ.).
15. Kisilyova A.N., Lopashinov P.M., Narkevich I.A., et al. Analysis of medicinal maintenance of preferential categories of citizens on the example of the Smolensk Region. Vestnik of the Smolensk State Medical Academy. 2017; 16 (4): 121–30 (in Russ.).
Review
For citations:
Petrukhina I.K., Yagudina R.I., Veyner N.V., Ryazanova T.K., Gladunova E.P., Kurkin V.A., Blinkova P.R., Zaitseva E.N. Peculiarities of administration of medications to patients with circulatory system diseases within the framework of the federal program of preferential provision of medicines. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(3):311-323. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.065

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.